Vanda Pharmaceuticals: Promising Pipeline and Regulatory Progress Drive Buy Rating
I'm PortAI, I can summarize articles.
Ram Selvaraju from H.C. Wainwright reiterated a Buy rating for Vanda Pharmaceuticals, maintaining a $20 price target. The rating is based on Vanda's promising pipeline and regulatory progress, including a Biologics License Application for imsidolimab and a New Drug Application for tradipitant. These developments, along with other candidates like HETLIOZ and Bysanti, suggest potential product approvals, enhancing Vanda's market position and financial performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments